

September 22, 2021

To  Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051  Company Code No. AUROPHARMA	To  The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001  Company Code No. 524804
--	--

Dear Sirs,


Sub: Press Release – Submission of first biosimilar filing with EMA

We enclose a copy of the Press Release that is being issued by the Company in connection with submission of first biosimilar filing with European Medicines Agency by CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company.

Please take the information on record.

Thanking you,

Yours faithfully,  
For AUROBINDO PHARMA LIMITED



B. Adi Reddy  
Company Secretary

Encl.: As Above

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,  
Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.  
Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500 038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

Hyderabad, India, September 22, 2021

### CuraTeQ submits its first biosimilar filing with European Medicines Agency (EMA)

Aurobindo Pharma Limited (along with its subsidiaries together referred to as “Aurobindo”) is pleased to announce that its subsidiary CuraTeQ Biologics Pvt Ltd. (CuraTeQ) has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for BP14, an oncology biosimilar product.

“The submission of BP14 MAA with EMA is an important beginning in our business evolution and positions CuraTeQ well in our mission of providing access to high quality biosimilars for cancer patients. We remain on track for filing our second product, another oncology biosimilar in the regulated markets, in this calendar year.

Earlier, we completed a successful Phase 1 clinical trial of a monoclonal antibody biosimilar product used for the treatment of multiple types of cancers. Another biosimilar from our oncology portfolio, currently in Phase 3 clinical studies has reached the 50% patient recruitment milestone this month and we hope to complete the recruitment in the next two quarters. Our focus on executing parallel clinical studies for multiple biosimilars in oncology segment is a testament of our commitment in expanding biosimilars treatment options for patients suffering from debilitating diseases,” said Dr. Satakarni Makkapati, CEO of CuraTeQ.

Mr. K. Nithyananda Reddy, Vice Chairman, Aurobindo said, “I am pleased to see that our commitment to biosimilars business, backed by world-class infrastructure and high caliber team is starting to see positive momentum with our first regulatory filing, with more products in licensure clinical trials. Through CuraTeQ, we aim to develop biosimilars for strengthening our focus in oncology and immunology segments. In a relatively short time span, the progression of our biosimilars pipeline is encouraging and we look forward to commercialize these products through our established commercial presence across the globe.”

### About Aurobindo Pharma Limited

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.

The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to [www.aurobindo.com](http://www.aurobindo.com)

## AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500 038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

*For further information or queries, please contact:*

Arvind Bothra  
Head - Investor Relations | Corporate Communications  
Phone: +91 40 66725401 / 66725000  
Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)

**Disclaimer:**

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

## AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,  
Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500 038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833